ClinicalTrials.gg
RecruitingNCT07233941CogMIGUpdated Feb 11, 2026

Neuropsychological Profile Characterization in Patients With Migraine: Cognitive Functioning and Psychological Variables

An observational study in Migraine and Migraine Disease, sponsored by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Observational

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
150
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 115 studies in Migraine Disorders with a site in Italy — 37 open to participants now, 47 under way, 13 of them phase 3. Migraine Disorders · Italy.

Planned enrollment
18th of 42
150 · median 108
Started
2025
with 8 others
Observational
42 of 115
26 open now
Primary completion
2027-05
later than 34 of 46 live
Registered
109th of 115
by date
Lead sponsor
5 of 115
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

Among the 115 studies in Migraine Disorders with a site in Italy, this one is the 18th largest by planned enrollment of the 42 observational ones that give a count, is one of 9 that started in 2025, is one of 42 observational ones, reaches primary completion later than 34 of the 46 other live ones, and was the 109th registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

37 of the 115 studies in Migraine Disorders with a site in Italy are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies in Migraine Disorders with a site in Italy, or all of them as a file.
02

Study summary

The overall objective is to define the neuropsychological profile of patients with migraine and evaluate its association with: psychological outcome measures (anxiety-depressive symptoms, pain catastrophizing, excessive worry, and coping strategies); the clinical profile of migraine; the prodromal, ictal, or interictal phase of the migraine attack; pharmacological therapy; and detoxification treatment in patients with migraine associated with medication overuse headache.

03

Conditions studied

  • Migraine
  • Migraine Disease

Keywords

  • migraine
  • cognition
  • cognitive impairment
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients aged between 18 and 65 years who suffer from migraines

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written .
  • Patients aged between 18 and 65 years.
  • Diagnosis of migraine according to the International Classification of Headache Disorders (ICHD-3) criteria.
  • Patients with a history of migraine for at least one year, to ensure the stability of the condition.
  • Stability of ongoing treatment for at least 3 months at baseline.
  • Understanding of the Italian language.

Exclusion criteria

Exclusion Criteria:

  • Severe medical or psychiatric conditions (depression, schizophrenia, psychosis) documented by specific previous diagnoses.
  • A history of alcohol or drug abuse.
  • Primary sensory deficits.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
150 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Cognitive functioning

    Neuropsychological test scores in migraine patients and proportion of participants with cognitive performance significantly different from age- and education-adjusted normative data.

    Time frame: 2 years

Secondary outcomes

  1. Cognitive functions and psychological, clinical aspects

    Correlation between cognitive performance scores and validated measures of anxiety/depression, pain catastrophizing, worry, coping strategies, headache-related impact and disability, and sleep quality in migraine patients.

    Time frame: 2 years

  2. Cognitive functions and different pharmacological treatments

    Differences in cognitive test performance scores among groups of migraine patients receiving different pharmacological treatments

    Time frame: 2 years

  3. Cognitive functions and medication overuse headache

    Change in cognitive test performance scores from pre-detoxification to post-detoxification treatment in patients with migraine and medication overuse headache.

    Time frame: 2 years

  4. Cognitive functions in the different phases of migraine

    Comparison of cognitive test performance scores between ictal and interictal migraine phases and across different durations of disease.

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A, Cady R, Dahlof CG, Dowson A, Tepper S. A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res. 2003 Dec;12(8):963-74. doi: 10.1023/a:1026119331193. PubMed 14651415 ↗
  • D'Amico D, Mosconi P, Genco S, Usai S, Prudenzano AM, Grazzi L, Leone M, Puca FM, Bussone G. The Migraine Disability Assessment (MIDAS) questionnaire: translation and reliability of the Italian version. Cephalalgia. 2001 Dec;21(10):947-52. doi: 10.1046/j.0333-1024.2001.00277.x. PubMed 11843865 ↗
  • Gil-Gouveia R, Martins IP. Clinical description of attack-related cognitive symptoms in migraine: A systematic review. Cephalalgia. 2018 Jun;38(7):1335-1350. doi: 10.1177/0333102417728250. Epub 2017 Aug 28. PubMed 28847155 ↗
  • Guerra LK, Rehfeldt IR, Lima MT, Petzl-Erler ML, de Messias IJ. BF and C3 genetic polymorphisms in Kaingang Indians from southern Brazil. Hum Hered. 1992;42(3):153-6. doi: 10.1159/000154058. PubMed 1511992 ↗
  • Gil-Gouveia R, Oliveira AG, Martins IP. The impact of cognitive symptoms on migraine attack-related disability. Cephalalgia. 2016 Apr;36(5):422-30. doi: 10.1177/0333102415604471. Epub 2015 Sep 8. PubMed 26350071 ↗
  • Vallesi A. On the utility of the trail making test in migraine with and without aura: a meta-analysis. J Headache Pain. 2020 Jun 3;21(1):63. doi: 10.1186/s10194-020-01137-y. PubMed 32493204 ↗
  • Pizer JH, Aita SL, Myers MA, Hawley NA, Ikonomou VC, Brasil KM, Hernandez KA, Pettway EC, Owen T, Borgogna NC, Smitherman TA, Hill BD. Neuropsychological Function in Migraine Headaches: An Expanded Comprehensive Multidomain Meta-Analysis. Neurology. 2024 Feb 27;102(4):e208109. doi: 10.1212/WNL.0000000000208109. Epub 2024 Jan 22. PubMed 38252898 ↗
  • Maleki N, Gollub RL. What Have We Learned From Brain Functional Connectivity Studies in Migraine Headache? Headache. 2016 Mar;56(3):453-61. doi: 10.1111/head.12756. Epub 2016 Feb 29. PubMed 26924634 ↗
  • Mondini S, Montemurro S, Pucci V, Ravelli A, Signorini M, Arcara G. Global Examination of Mental State: An open tool for the brief evaluation of cognition. Brain Behav. 2022 Aug;12(8):e2710. doi: 10.1002/brb3.2710. Epub 2022 Jul 21. PubMed 35861637 ↗
  • Stern Y. The concept of cognitive reserve: a catalyst for research. J Clin Exp Neuropsychol. 2003 Aug;25(5):589-93. doi: 10.1076/jcen.25.5.589.14571. No abstract available. PubMed 12815497 ↗
  • Nucci M, Mapelli D, Mondini S. Cognitive Reserve Index questionnaire (CRIq): a new instrument for measuring cognitive reserve. Aging Clin Exp Res. 2012 Jun;24(3):218-26. doi: 10.3275/7800. Epub 2011 Jun 20. PubMed 21691143 ↗
  • Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70. doi: 10.1111/j.1600-0447.1983.tb09716.x. PubMed 6880820 ↗
  • Meyer TJ, Miller ML, Metzger RL, Borkovec TD. Development and validation of the Penn State Worry Questionnaire. Behav Res Ther. 1990;28(6):487-95. doi: 10.1016/0005-7967(90)90135-6. PubMed 2076086 ↗
  • Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213. doi: 10.1016/0165-1781(89)90047-4. PubMed 2748771 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for May 2027, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Nov 18, 2025
StartActual
Sep 1, 2025
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Feb 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07233941
Lead sponsor
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Responsible party
Sponsor
First posted
Nov 18, 2025
Start date
Sep 1, 2025
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Feb 11, 2026

Study contacts

Danilo A Montisano, MD
principal investigator · Fondazione IRCCS Istituto Neurologico Carlo Besta

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion